Zynteglo(betibeglogene autotemcel)
Zynteglo (betibeglogene autotemcel) is a gene pharmaceutical. Betibeglogene autotemcel was first approved as Zynteglo on 2019-05-29. It is used to treat beta-thalassemia in the USA. It has been approved in Europe to treat beta-thalassemia.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Zynteglo
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Betibeglogene autotemcel
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Zynteglo | betibeglogene autotemcel | bluebird bio | N-125717 RX | 2022-08-17 | 1 products |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| zynteglo | Biologic Licensing Application | 2023-11-29 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| beta-thalassemia | Orphanet_848 | D017086 | D56.1 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
betibeglogene autotemcel, Zynteglo, Bluebird Bio Inc. | |||
| 2034-08-17 | Reference product excl. | ||
| 2029-08-17 | Orphan excl. | ||
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
13 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Beta-thalassemia | D017086 | Orphanet_848 | D56.1 | 2 | 2 | 2 | — | 2 | 6 |
| Thalassemia | D013789 | EFO_1001996 | D56 | 2 | 2 | 2 | — | 2 | 6 |
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | 2 | 2 | 1 | — | — | 3 |
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Betibeglogene autotemcel |
| INN | betibeglogene autotemcel |
| Description | Betibeglogene autotemcel, sold under the brand name Zynteglo, is a gene therapy for the treatment for beta thalassemia. It was developed by Bluebird Bio and was given breakthrough therapy designation by the US Food and Drug Administration in February 2015.
|
| Classification | Gene |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL4594311 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB16900 |
| UNII ID | MEE8487RTP (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Zynteglo – bluebird bio
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 465 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
44 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use